You are in:Home/Publications/Prevalence and clinical significance of nonorgan specific antibodies in patients with autoimmune thyroiditis as predictor markers for rheumatic diseases

Prof. Rania Hamdy Mohamed Afify Mahmoud Shaker :: Publications:

Title:
Prevalence and clinical significance of nonorgan specific antibodies in patients with autoimmune thyroiditis as predictor markers for rheumatic diseases
Authors: Basant M. Elnady, MDa,b, Naglaa M. Kamal, MDc,d,∗, Raneyah H.M. Shaker, MDe, Amal F. Soliman, MDa, Waleed A. Hasan, MDa, Hamed A. Alghamdi, MDd,f, Mohammed M. Algethamig, Mohamed Bilal Jajah, MDg
Year: 2016
Keywords: antidouble-stranded DNA, antiextractable-nuclear antigens, antinuclear antibodies, autoimmune thyroid diseases, rheumatoid factor, anticyclic-citrullinated peptides
Journal: Not Available
Volume: Not Available
Issue: Not Available
Pages: Not Available
Publisher: Not Available
Local/International: International
Paper Link: Not Available
Full paper Rania Hamdy Mohamed Afify Mahmoud Shaker_Prevalence_and_clinical_significance_of_nonorgan.1.pdf
Supplementary materials Not Available
Abstract:

Autoimmune diseases are considered the 3rd leading cause of morbidity and mortality in the industrialized countries. Autoimmune thyroid diseases (ATDs) are associated with high prevalence of nonorgan-specific autoantibodies, such as antinuclear antibodies (ANA), antidouble-stranded deoxyribonucleic acid (anti-dsDNA), antiextractable-nuclear antigens (anti-ENAs), rheumatoid factor (RF), and anticyclic-citrullinated peptides (anti-CCP) whose clinical significance is unknown. We aimed to assess the prevalence of various nonorgan-specific autoantibodies in patients with ATD, and to investigate the possible association between these autoantibodies and occurrence of rheumatic diseases and, if these autoantibodies could be considered as predictor markers for autoimmune rheumatic diseases in the future. This study had 2 phases: phase 1; in which 61 ATD patients free from rheumatic manifestations were assessed for the presence of these nonorgan-specific autoantibodies against healthy 61 control group, followed by 2nd phase longitudinal clinical follow-up in which cases are monitored systematically to establish occurrence and progression of any rheumatic disease in association to these autoantibodies with its influences and prognosis. Regarding ATD patients, ANA, anti-dsDNA, Anti-ENA, and RF were present in a percentage of (50.8%), (18%), (21.3%), and (34.4%), respectively, with statistically significance difference (P

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus